Network origin in Jutta Stuhlfauth first degree
Entity | Entity type | Industry | |
---|---|---|---|
Clearstream Banking AG
Clearstream Banking AG Regional BanksFinance Clearstream Banking AG engages in providing commercial banking services. Its services include settlement, custody, global securities, financing, investment fund, business and IT solutions and customer support. The company is headquartered in Eschborn, Germany.
1
| Subsidiary | Regional Banks | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Jutta Stuhlfauth via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Advitos GmbH
Advitos GmbH Medical SpecialtiesHealth Technology Advitos GmbH manufactures, develops, and markets liver support therapy devices. Its therapy device helps enhance the survival of patients with life-threatening liver diseases. The company was founded by Dr. Bernhard Kreyman in 2005 and is headquartered in Munich, Germany. | Medical Specialties | Director of Finance/CFO | |
V-Bio Ventures BV
V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent. | Investment Managers | Private Equity Investor | |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
Belgium | 4 |
Germany | 2 |
Sectoral
Commercial Services | 3 |
Health Technology | 2 |
Finance | 2 |
Operational
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Chief Administrative Officer | 1 |
Chief Operating Officer | 1 |
Director of Finance/CFO | 1 |
Most connected contacts
Insiders | |
---|---|
Katja Rosenkranz | 5 |
- Stock Market
- Insiders
- Jutta Stuhlfauth
- Company connections